Trial Profile
Rate and predictors for loss of remission and disease flare in patients with axial spondyloarthritis treated with antitumor necrosis factor (adalimumab, etanercept, or infliximab)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Infliximab (Primary)
- Indications Spondylarthritis
- Focus Therapeutic Use
- 13 Jun 2016 New trial record
- 01 Jun 2016 Results published in The Journal of Rheumatology